Dr. Shuguang Yuan Named a Clarivate Highly Cited Researcher 2026
Dr. Shuguang Yuan has been notified by Clarivate of his selection to the 2026 Highly Cited Researchers list, recognizing the sustained impact and influence of his scientific work.
The Highly Cited Researchers program is conducted by the Institute for Scientific Information (ISI) at Clarivate through a rigorous evaluation process combining quantitative data from the Web of Science Core Collection with qualitative analysis of researchers' publication and citation records.
Dr. Yuan's selection reflects the international impact of his research across computational structural biology, G protein-coupled receptor (GPCR) science, artificial intelligence-enabled drug discovery, and innovative therapeutics development.
Over the years, Dr. Yuan has conducted extensive research on GPCR structure, function, and drug discovery, while advancing the integration of artificial intelligence, computational biology, and experimental drug development. His work spans the continuum from fundamental biological questions to translational drug discovery, with a particular focus on uncovering novel therapeutic mechanisms and transforming scientific discoveries into potential medicines.
More recently, Dr. Yuan and his team have further developed an AI- and GPCR-driven drug discovery platform, applying computational technologies and experimental validation to identify novel targets and advance innovative drug candidates toward clinical development.
The Highly Cited Researchers program is conducted by the Institute for Scientific Information (ISI) at Clarivate through a rigorous evaluation process combining quantitative data from the Web of Science Core Collection with qualitative analysis of researchers' publication and citation records.
Dr. Yuan's selection reflects the international impact of his research across computational structural biology, G protein-coupled receptor (GPCR) science, artificial intelligence-enabled drug discovery, and innovative therapeutics development.
Over the years, Dr. Yuan has conducted extensive research on GPCR structure, function, and drug discovery, while advancing the integration of artificial intelligence, computational biology, and experimental drug development. His work spans the continuum from fundamental biological questions to translational drug discovery, with a particular focus on uncovering novel therapeutic mechanisms and transforming scientific discoveries into potential medicines.
More recently, Dr. Yuan and his team have further developed an AI- and GPCR-driven drug discovery platform, applying computational technologies and experimental validation to identify novel targets and advance innovative drug candidates toward clinical development.